company background image
NOVO B logo

Novo Nordisk CPSE:NOVO B Stock Report

Last Price

DKK 475.80

Market Cap

DKK 2.1t

7D

-7.8%

1Y

-51.8%

Updated

20 Jun, 2025

Data

Company Financials +

Novo Nordisk A/S

CPSE:NOVO B Stock Report

Market Cap: DKK 2.1t

Novo Nordisk (NOVO B) Stock Overview

Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details

NOVO B fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance3/6
Financial Health3/6
Dividends4/6

Rewards

Trading at 62.6% below our estimate of its fair value

Earnings are forecast to grow 12.4% per year

Earnings have grown 21.6% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Unstable dividend track record

Has a high level of debt


NOVO B Community Fair Values

Create Narrative

See what 766 others think this stock is worth. Follow their fair value or set your own to get alerts.

NOVO B logo
Novo Nordisk
AN
AnalystConsensusTarget
Consensus Narrative from 22 Analysts

Launch Of CagriSema And Catalent Expansion Will Drive Future Success

Key Takeaways Strategic acquisitions and capacity expansion are expected to enhance global manufacturing, supporting revenue growth through increased patient reach. Focus on innovative treatments and pipeline expansion aims to strengthen market position and could drive sustainable revenue and earnings growth.
View narrative
DKK 699.59
FV
32.0% undervalued intrinsic discount
14.95%
Revenue growth p.a.
10users have liked this narrative
2users have commented on this narrative
377users have followed this narrative
3 days ago author updated this narrative
NOVO B logo
Novo Nordisk
TO
Tokyo
Community Contributor

EU#2 - From Humble Beginnings to Global Powerhouse

Novo Nordisk, one of the world’s leading pharmaceutical companies, has a unique and inspiring origin story rooted in personal tragedy and scientific curiosity. The company’s roots date back to the 1920s, when Danish Nobel laureate August Krogh, a renowned physiologist, and his wife Marie, who suffered from type 2 diabetes, traveled to Canada.
View narrative
DKK 851.04
FV
44.1% undervalued intrinsic discount
22.49%
Revenue growth p.a.
17users have liked this narrative
11users have commented on this narrative
57users have followed this narrative
about 2 months ago author updated this narrative
NOVO B logo
Novo Nordisk
AN
AnalystHighTarget
Consensus Narrative from 22 Analysts

Emerging Diabetes And Obesity Trends Will Spur Positive Transformation

Key Takeaways Underestimated prescription growth, next-generation therapies, and global market expansion set the stage for outsized, sustained profit and market dominance. Ongoing pipeline innovation and strategic investment in manufacturing and digital health will drive durable revenue streams and cost-efficient scalability.
View narrative
DKK 900.00
FV
47.1% undervalued intrinsic discount
17.19%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
3 days ago author updated this narrative
NOVO B logo
Novo Nordisk
UN
Unike
Community Contributor

Novo Nordisk gears up for explosive growth in weight-loss and diabetes treatments

Catalysts Most Immediate Catalyst (1–2 Years): Weight-Loss Drug Boom: Novo Nordisk’s Wegovy (semaglutide) is dominating the obesity drug market , with demand outpacing supply. Obesity treatment is becoming a major new revenue stream.
View narrative
DKK 1.04k
FV
54.1% undervalued intrinsic discount
10.00%
Revenue growth p.a.
18users have liked this narrative
7users have commented on this narrative
38users have followed this narrative
4 months ago author updated this narrative
View Novo Nordisk Community

Novo Nordisk A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novo Nordisk
Historical stock prices
Current Share PriceDKK 475.80
52 Week HighDKK 1,033.20
52 Week LowDKK 380.00
Beta0.22
1 Month Change4.21%
3 Month Change-10.02%
1 Year Change-51.84%
3 Year Change21.02%
5 Year Change116.27%
Change since IPO17,554.92%

Recent News & Updates

Novo Nordisk A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 09
Novo Nordisk A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

Novo Nordisk A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 09
Novo Nordisk A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Why We're Not Concerned About Novo Nordisk A/S' (CPH:NOVO B) Share Price

Apr 24
Why We're Not Concerned About Novo Nordisk A/S' (CPH:NOVO B) Share Price
author-image

EU#2 - From Humble Beginnings to Global Powerhouse

CagriSema – a combination therapy for obesity and diabetes that may be even more effective than Wegovy.

We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Apr 07
We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Mar 14
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Feb 28
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year
author-image

Novo Nordisk will dominate with GLP-1 products boosting an 8% revenue spike

Are there any products or services that could move sales or earnings meaningfully?Most Immediate Catalyst (1–2 Years):Established GLP-1 Products:Ozempic & Rybelsus: driving robust sales and market pe

Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 10
Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Feb 07
The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Jan 09
Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Dec 23
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Nov 13
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
author-image

Expanding Horizons And Innovation Drive Bold Growth In Pharma's Global Landscape

Strategic market expansion and supply chain investments are set to boost Novo Nordisk's revenue growth through increased production and broader geographical reach.

Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Nov 01
Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Oct 09
Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Jul 27
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Jul 05
Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Shareholder Returns

NOVO BDK PharmaceuticalsDK Market
7D-7.8%-7.7%-5.4%
1Y-51.8%-50.9%-33.8%

Return vs Industry: NOVO B matched the Danish Pharmaceuticals industry which returned -50.9% over the past year.

Return vs Market: NOVO B underperformed the Danish Market which returned -33.8% over the past year.

Price Volatility

Is NOVO B's price volatile compared to industry and market?
NOVO B volatility
NOVO B Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement5.7%
10% most volatile stocks in DK Market9.6%
10% least volatile stocks in DK Market3.5%

Stable Share Price: NOVO B has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: NOVO B's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192377,406Lars Jorgensenwww.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVO B fundamental statistics
Market capDKK 2.11t
Earnings (TTM)DKK 104.62b
Revenue (TTM)DKK 303.14b
20.2x
P/E Ratio
7.0x
P/S Ratio

Is NOVO B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVO B income statement (TTM)
RevenueDKK 303.14b
Cost of RevenueDKK 46.53b
Gross ProfitDKK 256.61b
Other ExpensesDKK 151.99b
EarningsDKK 104.62b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 06, 2025

Earnings per share (EPS)23.57
Gross Margin84.65%
Net Profit Margin34.51%
Debt/Equity Ratio85.7%

How did NOVO B perform over the long term?

See historical performance and comparison

Dividends

2.4%
Current Dividend Yield
48%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/20 12:43
End of Day Share Price 2025/06/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 71 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research